International, Peer Reviewed, Open Access Journal

Journal of Clinical Pharmacology and Therapeutics
(ISSN: 2766-8347)

Submit Manuscript

Journal of Clinical Pharmacology and Therapeutics

Journal of Clinical Pharmacology and Therapeutics is an open access peer reviewed journal which provides latest updates in treatments, advanced procedures, technologies associated within the field of Pharmacology and other related sub-divisions.

Journal Features

Open Access

All the articles will be published under Open Access model.

Peer Review

Our editorial team performs strict peer-review process.

Publication Ethics

The journal follows standard guidelines to maintain transparency.

Submit Manuscript

The journal accepts all original articles, reviews and more.

About the Journal

Journal of Clinical Pharmacology and Therapeutics provide reports on optimal clinical use of various drugs and effects in treatment of patients.

Open Access - Journal of Clinical Pharmacology and Therapeutics

Editorial Board

Sana Irfan Khan - Journal of Clinical Pharmacology and Therapeutics

Sana Irfan Khan

Volunteering as a peer reviewer for submitted manuscripts
United States

ÖMER ALKAN - Journal of Clinical Pharmacology and Therapeutics

ÖMER ALKAN

Associate professor in the department of econometrics
Turkey

Bruno Trimarco - Journal of Clinical Pharmacology and Therapeutics

Bruno Trimarco

Federico II University of Naples (www.unina.it)
Federico II University of Naples, Director of Division of Cardiology, Coronary care unit and Cat Lab Business or sector Medical

Italy

Athanasia Papazafiropoulou - Journal of Clinical Pharmacology and Therapeutics

Athanasia Papazafiropoulou

General Hospital of Piraeus “Tzaneio”, 1st Department of Internal Medicine
Greece

Articles

J Clin Pharmacol Ther. 2023;4(1):JCPT-04-1037 | Open Access

Expression of TLR2 Promoted the Occurrence of TAM-Resistant in TPBC -BT474 Cells

Yunmei Wang, Jiao Yang, Yanwei Shen, Xiang wang, Guangxi Wang and Jin Yang

Objective: We have observed in previous clinical studies: the predictive performance of TLR2 for endocrine resistance was higher in HER2-positive Breast Cancer (BCa) than in other hormone receptor-positive BCa cases so, what about TLR2 expression in triple positive breast cancer cell lines (BT474)? This research aimed to evaluate the expression and establishment of drug resistance model of TLR2 in ... Read more

RESEARCH ARTICLE Updated Mar 03, 2023   PDF

J Clin Pharmacol Ther. 2023;4(1):JCPT-04-1036 | Open Access

New Approach to the R&D and the Consequences on Drug Pricing

Rubin Zareski

Achievement of sustainable economic stability and growth in the last 15 years was influenced by the absence or inconsistence of structural reforms in the major world economies. Negative or zero growth trends in the country’s GDP have significantly affected the Pharma industries, forcing them to shift and/or reduce the costs in all horizontal areas of business, affecting among ... Read more

RESEARCH ARTICLE Updated Jan 28, 2023   PDF

J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1035 | Open Access

Doravirine and Rilpivirine Intra Cellular Accumulation in the Clinical Setting

Ferrara M, Trevisan G, Marinaro L, Accardo G, Fantino S, Alladio F, Drappero E, Tettoni M, De Vivo E, Ianniello A, De Nicolò A, D’AvolioA, Calcagno A and Bonora S

Background: Doravirine (DOR) and Rilpivirine (RPV) are the NNRTIs currently most used in the clinical setting, in dual and triple drug regimens (2DR and 3DR). Intracellular (IC) Pharmacokinetics (PK) of these drugs has not been fully elucidated. Our aim was to compare plasma PK and IC accumulation in real-life experienced patients (pts).
Methods: Pts on DOR- and RPV-including Antiretroviral (... Read more

SHORT COMMUNICATION Updated Dec 22, 2022   PDF

J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1034 | Open Access

Pharmacokinetic and Pharmacodynamic Evaluation of a Sodium Bicarbonate Combination of Rabeprazole, a Proton-Pump Inhibitor, in Healthy Subjects

Yu Kyong Kim, Young-Sim Choi, Won Tae Jung, Kyu-Yeol Nam, Jae Seok Roh, Youn-Woong Choi, Sang-Min Cho, Do-Hyung Ki, Tae-Wan Kim, Hye J. Lee, Su Jeong, Min Kyu Park, Ha-Yeon Kim, Ji Hyeon Lee and Jun Gi Hwang

Purpose: Proton-pump inhibitors, such as rabeprazole, are prone to degradation in stomach acid. The use of Enteric-Coated (EC) forms minimizes this problem; however, these forms have slower onset time. The Pharmacokinetics (PK) and Pharmacodynamics (PD) of rabeprazole in a Fixed-Dose Combination (FDC) tablet with sodium bicarbonate, which was used to raise the intragastric pH, and in a conventional EC tablet ... Read more

RESEARCH ARTICLE Updated Dec 20, 2022   PDF

J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1033 | Open Access

Targeted Anticancer Therapy as a New Strategy of Treatment: Current and Future Scenery

Oliva B, Gómez NA and Fernández JR

Cancer is a disease with high incidence. Other therapies as surgery and radiotherapy are also used in the treatment of this disease. However, the effect adverse and the metastasis limited the use of these therapies. Target anticancer Targeted cancer treatment is an attractive approach where drugs or other substances which targets specific molecules to block the growth and spread of ... Read more

RESEARCH ARTICLE Updated Dec 16, 2022   PDF